2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.
Research is constantly being conducted for new biomarkers, especially for use in detection and predictive value for screening and imaging. Biomarkers can also enhance recurrence monitoring and help to understand treatment efficacy in patients with advanced disease, according to Petricoin.
Most research looks at biomarkers in general population screening but many recently-approved biomarkers for recurrence monitoring have been used for disease.
Related Content: